Shannon Elf
Tumor biology


AB, Bowdoin College, Biology and Music, English minor, 2003

PhD, Emory University, Graduate Division of Biological and Biomedical Sciences, 2013

Postdoctoral Fellow, Harvard Medical School, Brigham and Women’s Hospital, Department of Medicine, Division of Hematology, 2013-2018

Although the genes that drive the development of myeloid blood cancers have largely been defined, there are currently few effective targeted treatment strategies for these diseases. The development of imatinib to treat BCR/ABL-¬positive chronic myeloid leukemia remains the only true success story, with the majority of targeted therapies for myeloid malignancies demonstrating unimpressive clinical activity. This underscores the need to exploit the molecular understanding gained in the last decade through cancer exome sequencing to identify novel therapeutic vulnerabilities in myeloid malignancies. Research in my lab focuses on identifying unique molecular dependencies in myeloid blood cancers that can be targeted for therapeutic intervention, with the long¬ term goal of improving on current treatment regimens for these diseases. Currently, our work focuses on understanding the role of the unfolded protein response (UPR) in myeloproliferative neoplasms (MPN) and acute myeloid leukemia (AML). Using molecular, biochemical, and cellular approaches in both in vitro and in vivo models, we aim to dissect the molecular mechanisms underlying UPR activation in specific subsets of MPN and AML, and to use this mechanistic insight to develop rationally designed therapies to target the UPR in these challenging diseases. My work is currently supported by a Leukemia and Lymphoma Society Special Fellow Award and an NIH K99 Pathway to Independence Award.


Ludwig Center at the University of Chicago
5758 South Maryland Avenue MC 9006
Chicago, Illinois, U.S. 60637

T 773 702 0817
F 773 834 7233


You are now leaving Ludwig Cancer Research's website and are going to a website that is not operated by the association. We are not responsible for the content or availability of linked sites. Do you wish to continue?